Roanoke Asset Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $9.42M | Sell |
11,407
-1,160
| -9% | -$965K | 3.23% | 6 |
|
|
2024
Q4 | $9.7M | Buy |
12,567
+330
| +3% | +$273K | 3.12% | 8 |
|
|
2024
Q3 | $10.8M | Sell |
12,237
-45
| -0.4% | -$40.5K | 3.41% | 7 |
|
|
2024
Q2 | $11.1M | Sell |
12,282
-908
| -7% | -$726K | 3.67% | 5 |
|
|
2024
Q1 | $10.3M | Sell |
13,190
-15
| -0.1% | -$10.7K | 3.36% | 5 |
|
|
2023
Q4 | $7.7M | Sell |
13,205
-290
| -2% | -$169K | 2.85% | 7 |
|
|
2023
Q3 | $7.25M | Sell |
13,495
-2,020
| -13% | -$1.04M | 2.97% | 6 |
|
|
2023
Q2 | $7.28M | Sell |
15,515
-50
| -0.3% | -$21K | 2.88% | 6 |
|
|
2023
Q1 | $5.34M | Sell |
15,565
-10
| -0.1% | -$3.37K | 2.28% | 9 |
|
|
2022
Q4 | $5.7M | Sell |
15,575
-1,040
| -6% | -$369K | 2.59% | 8 |
|
|
2022
Q3 | $5.37M | Hold |
16,615
| – | – | 2.56% | 8 |
|
|
2022
Q2 | $5.39M | Sell |
16,615
-2,765
| -14% | -$830K | 2.42% | 8 |
|
|
2022
Q1 | $5.55M | Sell |
19,380
-1,740
| -8% | -$448K | 2.07% | 12 |
|
|
2021
Q4 | $5.83M | Sell |
21,120
-464
| -2% | -$118K | 1.93% | 16 |
|
|
2021
Q3 | $4.99M | Sell |
21,584
-110
| -0.5% | -$27.1K | 1.77% | 16 |
|
|
2021
Q2 | $4.98M | Buy |
21,694
+4,720
| +28% | +$948K | 1.73% | 17 |
|
|
2021
Q1 | $3.17M | Sell |
16,974
-20
| -0.1% | -$3.91K | 1.38% | 23 |
|
|
2020
Q4 | $2.87M | Sell |
16,994
-240
| -1% | -$35.8K | 1.36% | 24 |
|
|
2020
Q3 | $2.55M | Sell |
17,234
-1,955
| -10% | -$303K | 1.39% | 22 |
|
|
2020
Q2 | $3.15M | Sell |
19,189
-2,712
| -12% | -$416K | 1.82% | 17 |
|
|
2020
Q1 | $3.04M | Sell |
21,901
-125
| -0.6% | -$17.2K | 2.05% | 13 |
|
|
2019
Q4 | $2.9M | Sell |
22,026
-5,293
| -19% | -$614K | 1.45% | 24 |
|
|
2019
Q3 | $3.06M | Sell |
27,319
-820
| -3% | -$91.3K | 1.43% | 22 |
|
|
2019
Q2 | $3.12M | Sell |
28,139
-220
| -0.8% | -$25.9K | 1.41% | 23 |
|
|
2019
Q1 | $3.68M | Hold |
28,359
| – | – | 1.71% | 17 |
|
|
2018
Q4 | $3.28M | Sell |
28,359
-385
| -1% | -$43K | 1.74% | 16 |
|
|
2018
Q3 | $3.08M | Sell |
28,744
-15
| -0.1% | -$1.5K | 1.38% | 26 |
|
|
2018
Q2 | $2.45M | Sell |
28,759
-1,721
| -6% | -$141K | 1.18% | 32 |
|
|
2018
Q1 | $2.36M | Sell |
30,480
-935
| -3% | -$75.3K | 1.14% | 37 |
|
|
2017
Q4 | $2.65M | Sell |
31,415
-5,360
| -15% | -$456K | 1.27% | 31 |
|
|
2017
Q3 | $3.15M | Sell |
36,775
-2,065
| -5% | -$169K | 1.48% | 21 |
|
|
2017
Q2 | $3.2M | Buy |
38,840
+10,870
| +39% | +$887K | 1.51% | 24 |
|
|
2017
Q1 | $2.35M | Sell |
27,970
-4,975
| -15% | -$398K | 1.12% | 39 |
|
|
2016
Q4 | $2.42M | Sell |
32,945
-480
| -1% | -$35.7K | 1.1% | 42 |
|
|
2016
Q3 | $2.68M | Buy |
+33,425
| New | +$2.68M | 1.21% | 37 |
|
Other funds holding LLY
Roanoke Asset Management's LLY Position: Q1 2025 in Review
Roanoke Asset Management reduced its Eli Lilly (LLY) stake by 9.2% in Q1 2025, selling an estimated $965K and leaving 11,407 shares worth $9.42M. The position accounts for 3.23% of the portfolio, ranked #6.
Roanoke Asset Management first reported a position in LLY in Q3 2016 and has held it in 35 quarters since. The position peaked at $11.1M in Q2 2024. 3,919 funds tracked by Wall St. Rank hold LLY as of Q1 2025.
- Roanoke Asset Management held 11,407 shares of Eli Lilly worth $9.42M as of Q1 2025.
- Roanoke Asset Management sold 1,160 Eli Lilly shares in Q1 2025, an estimated $965K.
- Eli Lilly made up 3.23% of Roanoke Asset Management's portfolio in Q1 2025, its #6 holding.
- Roanoke Asset Management first reported a position in Eli Lilly in Q3 2016 and has held it in 35 quarters since.
- Roanoke Asset Management's Eli Lilly position peaked at $11.1M in Q2 2024.
- 3,919 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2025.
Based on Roanoke Asset Management's 13F filing for Q1 2025, filed 13 May 2025.